BioLoomics

About BioLoomics

BioLoomics is a biotechnology company focused on engineering Antibody Drug Conjugates (ADCs) to create safer and more effective cancer therapies. Their mission is to unlock the full potential of ADCs to improve patients' lives by overcoming the limitations of traditional ADCs.

Products & Services

Super-ADCs:Enhanced Antibody Drug Conjugates with membrane binding peptides to improve payload delivery, membrane loading, and internalization for better cancer therapy outcomes.

Therapeutic Programs:Development of best-in-class therapeutics targeting clinically validated oncology targets where traditional ADCs have been insufficient.

Directed Evolution:A discovery engine using bioinformatics and AI to design and test millions of peptide designs through a high-throughput wet-lab process, optimizing ADCs for membrane loading, internalization, and target-specific cytotoxicity.

Specialties

Antibody Drug Conjugates (ADCs) Cancer Therapeutics Directed Evolution Bioinformatics Artificial Intelligence (AI) High-Throughput Wet-Lab Processes

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 8700000 MR: - FA: $8.7 million FAN: 8700000	D: 2023-09-19 FD: 2023-09-19	8 investors

Seed Latest

2023-09-19

$8.7M

8 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Doug Chapnick, PhD

Founder & CEO

LinkedIn (Pro only)

K

Kurt Gish, PhD

CSO

N

Nicole Beach

Operations & People Manager

M

Michael Holden, PhD

Principal Scientist

A

Aaron Martin, PhD

Principal Scientist

M

Mike Minson, PhD

Scientist II

View 18 more team members with Pro

Unlock Full Team Directory

Recent News

BioLoomics Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised